Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;5(6):e001110.
doi: 10.1136/esmoopen-2020-001110.

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Susana Banerjee  1 , Antonio Gonzalez-Martin  2 , Philipp Harter  3 , Domenica Lorusso  4 , Kathleen N Moore  5 , Ana Oaknin  6 , Isabelle Ray-Coquard  7
Affiliations
Review

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Susana Banerjee et al. ESMO Open. 2020 Nov.

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with BRCA1/2 mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An ESMO Open - Cancer Horizons round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.

Keywords: PARP inhibitors; advanced ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SB: Institution research grants: Astrazeneca, Tesaro, GSK. Received honoraria for advisory boards Astrazeneca, Amgen, Clovis Oncology, Genmab, GSK, Immunogen, Merck Sereno, MSD, Mersana, Pfizer, Roche, Seattle Genetics, Tesaro. Support for travel or accommodation: Nucana, Tesaro. AGM: has served on advisory boards for Clovis Oncology, Amgen, AstraZeneca, Genmab/Seattle Genetics, Immunogen, MSD, Mersana, PharmaMar, Roche, and Tesaro/GSK, AMGEN, Merck, Novartis, Oncoinvent, received support for travel or accommodation from AstraZeneca, Pharmamar, GSK and Roche and institutional research funding from Roche and GSK/Tesaro. Lead Investigator PRIMA. PH: has served on advisory boards for Astra Zeneca, Roche, Tesaro, GSK, Lilly, Clovis, Immunogen, MSD/Merck, received honoraria (e.g. for lectures) from Astra Zeneca, Roche, Sotio, Tesaro, Stryker, ASCO, Zai Lab, MSD and institutional research funding from Astra Zeneca, Roche, Tesaro, Genmab, DFG, European Union, DKH, Genmab. DL: has served on advisory boards for Clovis Oncology, AstraZeneca, Genmab/Seattle Genetics, MSD, ImmunoGen, PharmaMar, Roche, MSD, Merck Serono, Amgen and Tesaro/GSK, received support for travel or accommodation from AstraZeneca, GSK and Roche and institutional research funding from Merck, GSK, Clovis, Pharmamar KM: has served on advisory boards for Aravive, Astra Zeneca, Abbvie, Eisai, Genentech/Roche, GSK/Tesaro, Immunogen, Merck, Myriad, Mersana, Tarveda, VBL Therapeutics. Lead Investigator SOLO-1. AO: has served on advisory boards for Clovis Oncology, AstraZeneca, Genmab/Seattle Genetics, MSD, Mersana, PharmaMar, Roche, Deciphera, Merck and Tesaro/GSK, received support for travel or accommodation from AstraZeneca, PharmaMar, Tesaro and Roche. IRC: has served on advisory boards for Clovis Oncology, AstraZeneca, Genmab/Seattle Genetics, MSD, Mersana, PharmaMar, Roche, and Tesaro/GSK, received support for travel or accommodation from AstraZeneca, GSK and Roche and institutional research funding from MSD, GSK. Lead Investigator PAOLA-1.

References

    1. Burger RA, Brady MF, Bookman MA, et al. . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:29;:2473–83. 10.1056/NEJMoa1104390 - DOI - PubMed
    1. Perren TJ, Swart AM, Pfisterer J, et al. . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:29:2484–96. 10.1056/NEJMoa1103799 - DOI - PubMed
    1. du Bois A, Reuss A, Pujade-Lauraine E, et al. . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des cancers de l'Ovaire (GINECO). Cancer 2009;115:1234–44. 10.1002/cncr.24149 - DOI - PubMed
    1. Ledermann JA. Parp inhibitors in ovarian cancer. Ann Oncol 2016;27:i40–4. 10.1093/annonc/mdw094 - DOI - PubMed
    1. Moore K, Colombo N, Scambia G, et al. . Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:27;:2495–505. 10.1056/NEJMoa1810858 - DOI - PubMed

MeSH terms

Substances